Pacific Biosciences of California PACB
$1.63 −$0.13 (-7.39%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $1.63 +0.28%
Open$1.69
Prev close$1.76
Day range$1.61 – $1.73
Volume13.69M
Market cap$510.07M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$40.56M+5.5% YoY
Operating profit-$37.00M+4.8% YoY
Net profit-$37.85M+0.4% YoY
Diluted EPS-$0.12+7.7% YoY
Free cash flow-$38.59M-107.3% YoY
Operating cash flow-$37.61M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin34.4%
Operating margin-100.1%
Net margin-81.3%
Return on assets-17.2%
Current ratio4.62
Liabilities / assets108.5%
Cash & investments$199.42M
Total debt$703.30M
Net cash (debt)-$503.88M
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $40.56M | $39.01M | $37.18M | $160.01M | $44.65M |
| Total Operating Revenue | $40.56M | $39.01M | $37.18M | $160.01M | $44.65M |
| Cost of Revenue | $27.09M | $26.37M | $24.34M | $114.23M | $28.08M |
| Gross Profit | $13.47M | $12.64M | $12.84M | $45.78M | $16.57M |
| Operating Expense | $50.47M | $57.25M | $66.99M | $603.34M | $57.76M |
| Selling and Admin Expenses | $29.42M | $33.39M | $31.15M | $141.49M | $34.05M |
| Research & Development | $20.22M | $23.02M | $19.61M | $97.31M | $22.88M |
| Depreciation & Amortization & Depletion | $833,000.00 | $833,000.00 | $833,000.00 | $364.54M | $833,000.00 |
| -Depreciation & Amortization | $833,000.00 | $833,000.00 | $833,000.00 | $364.54M | $833,000.00 |
| Operating Profit | -$37.00M | -$44.61M | -$54.15M | -$557.56M | -$41.20M |
| Net Non-Operating Interest Income (Expense) | -$2.06M | -$2.11M | -$1.74M | -$6.95M | -$1.74M |
| Non-Operating Interest Expense | $2.06M | $2.11M | $1.74M | $6.95M | $1.74M |
| Other Income (Expense) | $1.48M | $2.04M | $47.80M | $18.46M | $2.77M |
| Special Income (Charges) | $0.00 | $0.00 | $45.80M | $3.70M | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | $0.00 | $0.00 | -$18.70M | $0.00 |
| -Less:Write Off | $0.00 | $0.00 | $0.00 | $15.00M | $0.00 |
| -Gain on Sale of Property/Plant/Equipment | $0.00 | $0.00 | $45.80M | – | – |
| Other Non-Operating Income (Expenses) | $1.48M | $2.04M | $2.01M | $14.76M | $2.77M |
| Pretax Profit | -$37.58M | -$44.68M | -$8.09M | -$546.06M | -$40.17M |
| Tax | $269,000.00 | $58,000.00 | $184,000.00 | $318,000.00 | $202,000.00 |
| Net Profit | -$37.85M | -$44.74M | -$8.28M | -$546.38M | -$40.37M |
| Profit from Continuing Operations | -$37.85M | -$44.74M | -$8.28M | -$546.38M | -$40.37M |
| Net Income to Parent Company | -$37.85M | -$44.74M | -$8.28M | -$546.38M | -$40.37M |
| Net Income to Common Stockholders | -$37.85M | -$44.74M | -$8.28M | -$546.38M | -$40.37M |
| Basic EPS | -$0.12 | -$0.14 | -$0.03 | -$1.82 | -$0.13 |
| Diluted EPS | -$0.12 | -$0.14 | -$0.03 | -$1.82 | -$0.13 |
| Other Operating Expenses | – | – | $15.40M | – | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $721.10M | $751.85M | $782.37M | $784.08M | $784.08M |
| Total Current Assets | $307.85M | $338.64M | $369.52M | $375.05M | $375.05M |
| Cash and Cash Equivalents & Short-Term Investments | $199.42M | $236.87M | $275.96M | $279.51M | $279.51M |
| -Cash and Cash Equivalents | $55.91M | $61.00M | $56.27M | $63.71M | $63.71M |
| -Short Term Investments | $143.51M | $175.87M | $219.69M | $215.80M | $215.80M |
| Receivables | $38.32M | $31.10M | $29.35M | $35.45M | $35.45M |
| -Accounts Receivable | $38.32M | $31.10M | $29.35M | $35.45M | $35.45M |
| Inventory | $60.28M | $61.08M | $51.02M | $49.29M | $49.29M |
| Restricted Cash | $33,000.00 | $33,000.00 | $19,000.00 | $20,000.00 | $20,000.00 |
| Other Current Assets | $9.80M | $9.55M | $13.16M | $10.79M | $10.79M |
| Total Non-Current Assets | $413.24M | $413.21M | $412.85M | $409.03M | $409.03M |
| Net PPE | $68.69M | $67.30M | $65.22M | $65.84M | $65.84M |
| -Gross PPE | $68.69M | $67.30M | $65.22M | $158.31M | $158.31M |
| Goodwill and Other Intangible Assets | $329.93M | $330.85M | $331.87M | $332.89M | $332.89M |
| -Goodwill | $317.76M | $317.76M | $317.76M | $317.76M | $317.76M |
| -Other Intangible Assets | $12.16M | $13.08M | $14.10M | $15.12M | $15.12M |
| Other Non-Current Assets | $14.63M | $15.06M | $15.76M | $10.31M | $10.31M |
| Total Liabilities | $782.48M | $785.06M | $780.00M | $778.73M | $778.73M |
| Total Current Liabilities | $66.59M | $68.81M | $65.36M | $72.83M | $72.83M |
| Payables | $10.92M | $19.22M | $13.61M | $20.77M | $20.77M |
| -Accounts Payable | $10.92M | $19.22M | $13.61M | $20.77M | $20.77M |
| Current Accrued Expenses | $33.81M | $30.32M | $33.90M | $33.65M | $33.65M |
| Short-Term Debt and Capital Lease Obligation | $2.07M | $1.37M | $277,000.00 | $448,000.00 | $448,000.00 |
| -Current Capital Lease Obligation | $2.07M | $1.37M | $277,000.00 | $448,000.00 | $448,000.00 |
| Current Deferred Liabilities | $17.34M | $16.10M | $16.33M | $15.94M | $15.94M |
| Other Current Liabilities | $2.46M | $1.79M | $1.24M | $654,000.00 | $654,000.00 |
| Total Non-Current Liabilities | $715.88M | $716.26M | $714.64M | $705.90M | $705.90M |
| Long Term Debt and Capital Lease Obligation | $703.30M | $704.76M | $703.11M | $701.97M | $701.97M |
| -Long Term Debt | $643.06M | $644.33M | $644.11M | $645.38M | $645.38M |
| -Long Term Capital Lease Obligation | $60.24M | $60.42M | $59.00M | $56.59M | $56.59M |
| Non-Current Deferred Liabilities | $4.23M | $3.34M | $3.55M | $3.93M | $3.93M |
| Other Non-Current Liabilities | $8.35M | $8.16M | $7.98M | – | – |
| Total Equity | -$61.38M | -$33.21M | $2.37M | $5.35M | $5.35M |
| Stockholders' Equity | -$61.38M | -$33.21M | $2.37M | $5.35M | $5.35M |
| Capital Stock | $312,000.00 | $311,000.00 | $311,000.00 | $302,000.00 | $302,000.00 |
| -Common Stock | $312,000.00 | $311,000.00 | $311,000.00 | $302,000.00 | $302,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.73B | $2.72B | $2.71B | $2.70B | $2.70B |
| Retained Earnings | -$2.79B | -$2.75B | -$2.70B | -$2.70B | -$2.70B |
| Gains/Losses Not Affecting Retained Earnings | -$819,000.00 | -$503,000.00 | -$147,000.00 | $457,000.00 | $457,000.00 |
| -Accumulated Depreciation | – | – | – | -$92.47M | -$92.47M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$37.61M | -$35.58M | -$44.69M | -$111.21M | -$19.07M |
| Net cash flow from continuing operations | -$37.61M | -$35.58M | -$44.69M | -$111.21M | -$19.07M |
| Net Income from Continuing Operations | -$37.85M | -$44.74M | -$8.28M | -$546.38M | -$40.37M |
| Gain/Loss from Continuing Operations | $0.00 | $0.00 | -$48.10M | – | – |
| Depreciation & Depletion & Amortization | $4.77M | $4.52M | $4.07M | $386.41M | $4.65M |
| Deferred Tax | $0.00 | $0.00 | $0.00 | -$546,000.00 | $0.00 |
| Other Non-Cash Items | $356,000.00 | $225,000.00 | $225,000.00 | -$17.01M | $232,000.00 |
| Change in Working Capital | -$11.95M | -$5.99M | $3.17M | $4.44M | -$2.28M |
| -Change in Receivables | -$7.22M | -$1.75M | $6.10M | -$7.92M | -$4.83M |
| -Change in Inventory | -$1.39M | -$11.26M | -$3.21M | -$1.42M | -$6.26M |
| -Change in Prepaid Assets | -$326,000.00 | $1.86M | -$2.29M | $8.51M | $717,000.00 |
| -Change in Payables and Accrued Expense | -$6.31M | $3.40M | -$4.01M | $5.64M | $6.28M |
| -Change in Other Current Liabilities | $1.17M | $2.20M | $6.56M | -$470,000.00 | $2.41M |
| -Change In Other Working Capital | $2.13M | -$442,000.00 | $19,000.00 | $101,000.00 | -$584,000.00 |
| Net cash flow from investing | $31.11M | $40.07M | $35.86M | $115.45M | $26.03M |
| Net Cash Flow from Continuing Investing Activities | $31.11M | $40.07M | $35.86M | $115.45M | $26.03M |
| Net PPE Purchase and Sale | -$988,000.00 | -$1.56M | -$3.04M | -$2.71M | -$861,000.00 |
| Net Intangibles Purchase and Sale | $0.00 | -$2.06M | -$5.00M | -$5.00M | $0.00 |
| Net Investment Purchase and Sale | $32.10M | $43.68M | -$4.20M | $123.16M | $26.89M |
| Net Other Investing Changes | $0.00 | $0.00 | $48.10M | – | – |
| Financing Cash Flow | $1.46M | $255,000.00 | $1.44M | $3.43M | $0.00 |
| Net Cash Flow from Continuing Financing Activities | $1.46M | $255,000.00 | $1.44M | $3.43M | $0.00 |
| Proceeds from Stock Option Exercised | $1.46M | $255,000.00 | $1.44M | $3.43M | $0.00 |
| Ending Cash Balance | $57.57M | $62.61M | $56.27M | $65.26M | $65.26M |
| Net Change in Cash | -$5.04M | $4.74M | -$7.40M | $7.67M | $6.96M |
| Beginning Cash Balance | $62.61M | $56.27M | $65.26M | $57.59M | $58.30M |
| Free Cash Flow | -$38.59M | -$39.19M | -$52.73M | -$118.92M | -$19.93M |
| Net Business Purchase and Sale | – | – | – | $0.00 | – |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | $0.00 |
| Net Common Stock Issuance | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on PACB.
Sign in to join the discussion.